JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline. Jazz Pharmaceuticals plans to expand indications for two oncology drugs, namely zanidatamab and Zepzelca.

5 小时之前 · The vaccines are personalised via neoantigens extracted from the patient’s tumour tissue during tumour removal surgery. Credit: Shutterstock / Pormezz. All nine patients in a Phase I investigator-led trial of a personalised kidney cancer vaccine have successfully generated anti-cancer immune ...

Clinical Trials Arena Excellence Awards 2024 – Winners Announced! The Clinical Trials Arena Excellence Awards Winners have been announced! To see the full list you can download the full…

2024年12月23日 · Most significant clinical trials of 2024. From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.

1 天前 · The trial aims to enrol 240 participants from families with mutations in one of the three key genes and a family history of Alzheimer’s. Credit: Shutterstock / New Africa. A US university has launched a prevention trial examining the use of …

Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD. US-based pharmaceutical company Cumberland Pharmaceuticals has reported positive top-line outcomes from a Phase II trial of ifetroban as a potential…

2025年1月13日 · Figure 1: Obesity clinical trials and innovator drug obesity trials, 2015-2025. Credit: GlobalData. There are over 300 glucagon-like peptide-1 receptor (GLP-1R) drugs in an active stage of development as the astounding success of Novo Nordisk’s GLP-1R obesity drug, Wegovy, has ignited a surge in ...

Clinicaltrialsarena.com covers every aspect of the drug development and research process, from conception to pre-FDA approval.. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone – from senior management through to research and QA staff – …

3 天之前 · Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving progression-free survival (PFS) in a Phase III trial, further supporting a full approval.. The company’s active-controlled, open-label BREAKWATER trial (NCT05217446) evaluating a combination of Pfizer’s Braftovi (encorafenib), Eli Lilly’s Erbitux (cetuximab) and mFOLFOX6 ...

2023年6月30日 · According to a report by GlobalData, the market for obesity drugs is predicted to be worth $37.1bn in 2031.GlobalData is a parent company of the Clinical Trials Arena.. As more trials take place globally, not only will this help to provide a wider range of treatments for patients but will also assist the unmet need of lack of supply.Most of the current obesity treatments that target glucagon ...